Cravath Publishes Winter 2026 Issue of Alumni Journal
Lauren
Piechocki
Practice Area Attorney, Corporate
Lauren Piechocki is an attorney in Cravath’s Corporate Department and focuses her practice on real estate. Her experience includes representing institutional and individual clients, including developers and investors, in all areas of real estate transactions, including real estate finance, acquisitions and dispositions for office, retail and mixed‑use building and development sites across the United States.
Ms. Piechocki was recognized by Super Lawyers as a Rising Star for her work in real estate in 2021.
Ms. Piechocki received a B.A. cum laude from Syracuse University in 2005 and a J.D. from Hofstra University School of Law in 2012.
Ms. Piechocki joined Cravath in 2022. Prior to joining Cravath, she was associated with a law firm in New York. She is admitted to practice before the U.S. District Courts for the Southern District of New York, Eastern District of New York, Southern District of New York Bankruptcy Court and the Eastern District of New York Bankruptcy Court.
Ms. Piechocki was recognized by Super Lawyers as a Rising Star for her work in real estate in 2021.
Ms. Piechocki received a B.A. cum laude from Syracuse University in 2005 and a J.D. from Hofstra University School of Law in 2012.
Ms. Piechocki joined Cravath in 2022. Prior to joining Cravath, she was associated with a law firm in New York. She is admitted to practice before the U.S. District Courts for the Southern District of New York, Eastern District of New York, Southern District of New York Bankruptcy Court and the Eastern District of New York Bankruptcy Court.
Education
-
J.D., 2012, Hofstra University School of Law
-
B.A., 2005, Syracuse UniversityDean's Scholar Maxwell Citizen Education Conference Scholar, cum laude
Admitted In
- New York
Rankings
Super Lawyers
- Rising Stars - New York (2021)
Deals & Cases
March 02, 2026
Select Medical’s $3.9 Billion Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS
On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.
Deals & Cases
February 28, 2026
Paramount’s $110 Billion Acquisition of Warner Bros. Discovery, Inc.
On February 27, 2026, Paramount Skydance Corporation (“Paramount”) and Warner Bros. Discovery, Inc. ("WBD") announced they have entered into a definitive merger agreement under which Paramount will acquire WBD. Under the terms of the agreement, Paramount will pay $31.00 per share in cash for all outstanding shares of WBD. The transaction values WBD at an enterprise value of $110 billion, and has been unanimously approved by the Boards of Directors of both companies. Cravath is representing Paramount in connection with the transaction.
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Deals & Cases
February 02, 2026
Hain Celestial Group’s Sale of North American Snacks Business to Snackruptors Inc.
On February 2, 2026, Hain Celestial Group, a leading global health and wellness company, announced that it has reached a definitive agreement to sell its North American Snacks business, including Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks, to Snackruptors Inc., a Canadian, family‑owned snacks manufacturer, for $115 million in cash. Cravath is representing Hain Celestial Group in connection with the transaction.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
Lauren Piechocki is an attorney in Cravath’s Corporate Department and focuses her practice on real estate. Her experience includes representing institutional and individual clients, including developers and investors, in all areas of real estate transactions, including real estate finance, acquisitions and dispositions for office, retail and mixed‑use building and development sites across the United States.
Ms. Piechocki was recognized by Super Lawyers as a Rising Star for her work in real estate in 2021.
Ms. Piechocki received a B.A. cum laude from Syracuse University in 2005 and a J.D. from Hofstra University School of Law in 2012.
Ms. Piechocki joined Cravath in 2022. Prior to joining Cravath, she was associated with a law firm in New York. She is admitted to practice before the U.S. District Courts for the Southern District of New York, Eastern District of New York, Southern District of New York Bankruptcy Court and the Eastern District of New York Bankruptcy Court.
Ms. Piechocki was recognized by Super Lawyers as a Rising Star for her work in real estate in 2021.
Ms. Piechocki received a B.A. cum laude from Syracuse University in 2005 and a J.D. from Hofstra University School of Law in 2012.
Ms. Piechocki joined Cravath in 2022. Prior to joining Cravath, she was associated with a law firm in New York. She is admitted to practice before the U.S. District Courts for the Southern District of New York, Eastern District of New York, Southern District of New York Bankruptcy Court and the Eastern District of New York Bankruptcy Court.
Education
-
J.D., 2012, Hofstra University School of Law
-
B.A., 2005, Syracuse UniversityDean's Scholar Maxwell Citizen Education Conference Scholar, cum laude
Admitted In
- New York
Rankings
Super Lawyers
- Rising Stars - New York (2021)
Deals & Cases
March 02, 2026
Select Medical’s $3.9 Billion Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS
On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.
Deals & Cases
February 28, 2026
Paramount’s $110 Billion Acquisition of Warner Bros. Discovery, Inc.
On February 27, 2026, Paramount Skydance Corporation (“Paramount”) and Warner Bros. Discovery, Inc. ("WBD") announced they have entered into a definitive merger agreement under which Paramount will acquire WBD. Under the terms of the agreement, Paramount will pay $31.00 per share in cash for all outstanding shares of WBD. The transaction values WBD at an enterprise value of $110 billion, and has been unanimously approved by the Boards of Directors of both companies. Cravath is representing Paramount in connection with the transaction.
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Deals & Cases
February 02, 2026
Hain Celestial Group’s Sale of North American Snacks Business to Snackruptors Inc.
On February 2, 2026, Hain Celestial Group, a leading global health and wellness company, announced that it has reached a definitive agreement to sell its North American Snacks business, including Garden Veggie Snacks™, Terra® chips and Garden of Eatin’® snacks, to Snackruptors Inc., a Canadian, family‑owned snacks manufacturer, for $115 million in cash. Cravath is representing Hain Celestial Group in connection with the transaction.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.